Burzynski Research Institute (BZYR) Non-Current Assets (2011 - 2019)

Burzynski Research Institute (BZYR) posted Non-Current Assets of -$99.0 for Q1 2019, down 157.89% sequentially from $171.0 in Q4 2016.

Burzynski Research Institute (BZYR) Non-Current Assets (2011 - 2019) Analysis & Trends

Burzynski Research Institute has reported Non-Current Assets for 7 years, with the latest figure at -$99.0 in Q1 2019.

Quarterly Non-Current Assets changed N/A year-over-year to -$99.0 in Q1 2019, while the trailing twelve-month figure through Nov 2019 was -$99.0 (changed N/A YoY) and the FY2019 annual result came in at -$99.0, changed N/A from the prior year.
Non-Current Assets fell to -$99.0 in Q1 2019 per BZYR's latest filing, from $171.0 in the prior quarter.
Over five years, Non-Current Assets peaked at $1368.0 in Q1 2015 and troughed at -$99.0 in Q1 2019.
A 3-year average of $673.0 and a median of $684.0 in 2016 frame the typical range for Non-Current Assets.
The sharpest annual moves came in 2015 and 2016: Non-Current Assets plunged 33.33% in 2015, then sank 80.0% in 2016.
Over 3 years, Non-Current Assets stood at $855.0 in 2015, then tumbled by 80.0% to $171.0 in 2016, then slumped by 157.89% to -$99.0 in 2019.
According to Business Quant data, Non-Current Assets over the past three periods registered -$99.0, $171.0, and $342.0 for Q1 2019, Q4 2016, and Q3 2016 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	1.96 Bn
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	938.60 Mn
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	6.80 Bn
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	468.65 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	18.06 Bn
10	Burzynski Research Institute	1.31 Mn	1.31 Mn	-	-

Download Data